AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00112151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HighT
Description: High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
Study NCT01990599 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasopharyngeal Tube
Study NCT01712386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot
Study NCT01712386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot placebo
Study NCT04497558 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endometrium biopsy
Description: In the experimental group, those patients undergo endometrial receptivity array. In the control group, those patients do not receive any treatment before next cycle of transfer. In the experimental group, according to the results of endometrial receptivity array, the transplantation time will be adjusted and retransplantation will be carried out. In the control group, no intervention will be performed.
Study NCT00862212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Intervention
Description: At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
Study NCT00434590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric coated mycophenolate sodium (Myfortic®)
Study NCT00434590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric coated mycophenolate sodium (Myfortic®)
Study NCT01547728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant antithrombin (rhAT)
Description: Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
Study NCT03391466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously following a conditioning chemotherapy regimen of fludarabine and cyclophosphamide
Study NCT03391466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
Description: Platinum-containing salvage chemotherapy (R-ICE, R-DHAP, R-ESHAP, or R-GDP as selected by treating investigator) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
Study NCT00918398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 514 mg oral solution, single dose
Study NCT00918398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
Study NCT00918398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: 500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
Study NCT05181696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chest X-ray
Description: Retrospective analysis of chest x-rays of patients with COVID-19
Study NCT03391466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study NCT03391466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study NCT04498429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Cueing Protocol
Description: The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. In addition to verbal cueing, the manual cueing group will receive hands-on tactile facilitation from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
Study NCT04498429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal Cueing Protocol
Description: The first 5 repetitions will include part to whole task practice of partial sit to stand using scripted verbal cueing to facilitate understanding of the task. The goal is to improve midline orientation and alignment during the task of moving from sitting to standing. The verbal cueing protocol consists of verbal cueing from a trained physical therapist to facilitate appropriate midline weight shift during the sit to stand activity for the series of 40 training repetitions.
Study NCT02039336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Study NCT03803683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mLab App
Description: The mLab App is a web application that uses an image processing algorithm to interpret the results of the OraQuick® In-Home HIV Test.
Study NCT03803683 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Prevention Information
Description: Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.
Study NCT03803683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Prevention Information
Description: Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.
Study NCT03803683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIV Home Tests
Description: Youth randomized into this arm will receive OraQuick® In-Home HIV Test.
Study NCT04519138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endodrill Model X
Description: The investigational device Endodrill Model X is used for biopsy sampling in the upper gastrointestinal tract
Study NCT04519138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine-needle aspiration/biopsy
Description: The standard method is used for biopsy sampling in the upper gastrointestinal tract
Study NCT05982379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology Based Motivation Program
Description: A 10-week Technology Based Motivation Program was given to the intervention group. The website and four training modules were used with the children in the intervention group. Nine coaching interviews with each child (once a week) were conducted over WhatsApp. The children were encouraged to do progressive relaxation and breathing exercises at least twice a week, and eight therapeutic stories (once a week) were sent to the child's phone in the form of animation.~Three training modules were used with the primary caregivers, and coaching interviews were conducted on WhatsApp twice during the program. Primary caregivers practiced progressive relaxation and breathing exercises at least twice a week. In addition, eight motivation messages were sent to the child and primary caregiver, and 24/7 consultancy was provided.
Study NCT01620047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
Study NCT01620047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
Study NCT01620047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
Study NCT03759197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 188-0551 Spray
Description: Topical Spray containing active drug
Study NCT03759197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Spray
Description: Topical Spray containing no active drug
Study NCT04804436 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: he real-time PCR amplification was performed in a final volume of 20μL reaction mixture, including 10 ng of genomic DNA, 5 µL of TaqMan® Universal PCR Master Mix, and 0.5 µL of 40X TaqMan® assay. Thermal cycling conditions were as follows: initial denaturation at 94℃ for 3 min, 40 cycles of 94℃ for 15 s, and 60°C for 1 min. The Rotor-Gene Q Series Software Version Q 2.3.1 (Rotor-Gene Q Series, Ziagen) was used for allelic discrimination.
Study NCT01716637 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Study NCT01716637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.
Study NCT03803683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIV Home Tests
Description: Youth randomized into this arm will receive OraQuick® In-Home HIV Test.
Study NCT00538564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: 10mg oral tablets taken 3 times a week for 2 months
Study NCT00538564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets taken orally 3 times a week for 2 months
Study NCT01241084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antileukotrienes + Lactobacillus reuteri
Description: Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
Study NCT01241084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antileukotrienes + Placebo
Description: Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
Study NCT04565353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flu shot text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study NCT00729924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg orally every 12 hours for 7 days
Study NCT01199107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
Study NCT01199107 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: 75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
Study NCT01199107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
Study NCT01199107 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Intervention
Description: 30 minutes of wellness education prior to Prolonged Exposure
Study NCT02643329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-Gliclazide Tablet 80mg
Description: BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
Study NCT02643329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diamicron 80mg Tablet
Description: Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
Study NCT02039336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0325901
Study NCT02039336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT03293797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abbreviated-Mindfulness-based Therapy
Description: A-MBT will be delivered in group format, 120 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
Study NCT05297123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: All-trans retinoic acid (ATRA) 20mg 3 times a day for 8 weeks.
Study NCT05297123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given)
Study NCT05297123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Realgar-Indigo naturalis formula
Description: 60 mg/kg/d for 8 weeks
Study NCT02977156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexa-Vec
Description: IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
Study NCT02977156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
Study NCT02655653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid administered
Description: Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
Study NCT02655653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid administered
Description: Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
Study NCT00522184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-articular injection of etanercept
Study NCT00522184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular injection of steroid
Study NCT04305912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: Subjects will be randomized to wear somofilcon A daily disposable lenses.
Study NCT04305912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: verofilcon A
Description: Subjects will be randomized to wear verofilcon A daily disposable lenses.
Study NCT00950287 — intervention group
Intervention type: DEVICE
Intervention: No intervention
Description: The recordings will be performed in neonatal units with the preterm infant remaining in usual condition with limitations of external stimulation during the study period. The usual monitor will remain in function. The intervention of the nurses in case of apnea will not be modified during the study period. The recording will be obtained from derivation of the signal usually recorded by the monitor in use completed in one centre by a polysomnographic recording (Medtronics France SA), in order to test a possible influence of the sleep status on the detection.
Study NCT04629885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin 400 IU vaginal gel
Study NCT04629885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo gel with identical appearance to the test product, used as reference treatment.
Study NCT04714411 — intervention group
Intervention type: DRUG
Intervention: Omadacycline
Description: Omadacycline monotgherapy
Study NCT02638090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: Administered per treatment arm guidelines.
Study NCT02638090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Administered per treatment arm guidelines.
Study NCT01573143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;
Study NCT01573143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.
Study NCT00913432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Description: 3 mg/kg/day oral route
Study NCT00913432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Description: masitinib 6 mg/kg/day oral route
Study NCT02638090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered per treatment arm guidelines.
Study NCT04568096 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized All-Trans Retinoic acid plus oral Tamoxifen
Description: After randomization and standard treatment The infected patients will receive Aerosolized All-Trans Retinoic Acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day as inhaled All-Trans Retinoic Acid therapy plus tamoxifen 20mg orally once daily. for 14 days
Study NCT04568096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study NCT02638090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered per treatment arm guidelines.
Study NCT04317105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy
Study NCT04317105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04317105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan
Study NCT04317105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV
Study NCT02656043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XPF-005
Description: Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.
Study NCT02656043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03176745 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout
Description: determination of lung clearance index using SF6 multiple breath washout
Study NCT04068597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCS1477
Description: Oral capsule
Study NCT04068597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: oral capsule
Study NCT04068597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral tablet
Study NCT04068597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Powder suspension for Injection
Study NCT04068597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral tablet
Study NCT04438785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The intervention consists of myofunctional therapy (MT) using the AirwayGym app.
Description: Intervention. Patient newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the App AirwayGym 20 minutes a day during 90 days.
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) Oral ART
Description: SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC) Oral ART
Description: SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral RPV
Description: RPV 25 mg tablets
Study NCT03635788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral RPV
Description: RPV 25 mg tablets